Nanoparticle News and Research

RSS

In nanotechnology, a particle is defined as a small object that behaves as a whole unit in terms of its transport and properties. It is further classified according to size: in terms of diameter, fine particles cover a range between 100 and 2500 nanometers, while ultrafine particles, on the other hand, are sized between 1 and 100 nanometers.

Groundbreaking cancer treatment studies to be unveiled at AAPS National Biotechnology Conference

Cancer studies from Mercer University headline groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference (NBC).

13 May 2011

Merrimack, PharmaEngine collaborate to develop and commercialize PEP02 in Asia and Europe

PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. announced today the execution of an agreement under which PharmaEngine grants back to Merrimack the rights to develop, manufacture, and commercialize PEP02 in Asia and Europe, with the exception of Taiwan.

9 May 2011

New nano-vault delivery system can fight cancer

UCLA scientists have discovered a way to wake up the immune system to fight cancer by delivering an immune system-stimulating protein in a nanoscale container called a vault directly into lung cancer tumors, harnessing the body's natural defenses to fight disease growth.

4 May 2011

New MIT drug-delivery nanoparticle could target any type of tumor

MIT chemical engineers have designed a new type of drug-delivery nanoparticle that exploits a trait shared by almost all tumors: They are more acidic than healthy tissues.

4 May 2011

New nanoparticle imaging agent can help diagnose heart disease, breast cancer

Scientists are reporting development of a process for producing large quantities of a much-needed new imaging agent for computed tomography scans in heart disease, breast cancer and other diseases, and the first evidence that the material is safe for clinical use.

28 Apr 2011

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer.

27 Apr 2011

Researchers package drug-loaded 'nanodisks' into vault nanoparticles for therapeutic drug delivery

There's no question, drugs work in treating disease. But can they work better, and safer?

22 Apr 2011

Major pharmaceutical company, Access sign deal for RNAi therapeutics

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major pharmaceutical company to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.

15 Apr 2011

First Edition: April 4, 2011

Today's health policy news coverage includes reports about Republican lawmakers' plans to make dramatic changes to Medicare and Medicaid as they seek to cut $4 trillion from the budget over the next 10 years.

4 Apr 2011

Study: Nanoparticles can prevent nickel-induced dermatitis

Tiny particles only billionths of a meter in diameter-about two thousand would fit across the width of a human hair-could offer big hope in a small package to the many millions of people who are allergic to the nickel in everything from jewelry to coins and cell phones, say scientists at Brigham and Women's Hospital.

4 Apr 2011

New ‘nanotech’ weapon against drug-resistant superbugs

Scientists at the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research – Almaden have developed the first biodegradable polymer nanoparticles to combat drug-resistant superbugs, such as Methicillin-Resistant Staphylococcus aureus (MRSA). These nanoparticles can selectively kill the bacteria without destroying healthy red blood cells, and being biodegradable, have great potential to treat infectious diseases in the body. This was reported today in the leading scientific journal, Nature Chemistry [(2011) DOI: 10.1038/nchem.1012].

3 Apr 2011

Champions enters exclusive license agreement with BCCA for Irinophore C

Champions Biotechnology, Inc. announced today that it has exercised an option to license Irinophore C, a liposomal formulation of Irinotecan, from the BC Cancer Agency in British Columbia, Canada.

2 Apr 2011

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

High-density lipoprotein's hauls excess cholesterol to the liver for disposal, but new research suggests "good cholesterol" can also act as a special delivery vehicle of destruction for cancer.

1 Apr 2011

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has completed enrollment in its ALN-VSP Phase I multi-center, multinational, open label, dose escalation clinical trial.

1 Apr 2011

AACR to honor UNC scientist with $181,000 grant for breast cancer research

The American Association for Cancer Research announced today that Carey Anders, MD, assistant professor of medicine and a member of UNC Lineberger Comprehensive Cancer Center will receive a Breast Cancer Research Foundation-AACR Grant for Translational Breast Cancer Research. The $181,000 grant will be presented at the organization's 102nd Annual Meeting, to be held in Orlando, Florida, April 2-6.

28 Mar 2011

Contrast agent for tumor diagnostics

X-rays are not the only way: visible and especially infrared light can also be used to image human tissue. The effectiveness of optical imaging processes can be significantly improved with suitable dyes used as contrast agents. In the journal Angewandte Chemie, a team led by Wenbin Lin at the University of North Carolina (Chapel Hill, USA) has now introduced a novel contrast agent that marks tumor cells in vitro. The dye is a phosphorescent ruthenium complex incorporated into nanoparticles of a metal–organic coordination polymer, which allows an extraordinarily high level of dye loading.

23 Mar 2011

Scientists create organic nanoparticle to treat cancer and deliver drugs

A team of scientists from Princess Margaret Hospital have created an organic nanoparticle that is completely non-toxic, biodegradable and nimble in the way it uses light and heat to treat cancer and deliver drugs.

22 Mar 2011

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

21 Mar 2011

Alnylam to defend against Tekmira complaint

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is reporting the filing of a complaint by Tekmira Pharmaceuticals Corporation in the Business Litigation Session (BLS) of the Massachusetts Superior Court. The complaint alleges misappropriation and misuse of information, amongst other allegations.

18 Mar 2011

Scientists create new drug delivery system to treat cancer

Scientists in Syracuse University's Chemistry Department have created a new drug delivery system expected to advance the effectiveness of cancer-killing drugs. It uses gold nanoparticles with attached DNA that binds to a proven anti-cancer drug, Doxorubicin or DOX.

16 Mar 2011